The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in patients with type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [4]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294
Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 2
- Toto RD, 2013, J Am Soc Nephrol, 24
- 10.1056/NEJMsr077003 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 698
Kato, E. T., Das, S. R., & McGuire, D. K. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.12.010 · Cited by 7
Insight Into the Perioperative Management of Type 2 Diabetes
Zaidi, S. O., Khan, Y., Razak, B. S., & Malik, B. H. (2020) · Cureus · doi:10.7759/cureus.6878 · Cited by 9
Primary Prevention of CVD with Aspirin: Benefits vs Risks
Weisman (2021) · The Journal of Family Practice · doi:10.12788/jfp.0222 · Cited by 7
Yu, H., Basu, S., Tang, W., Penland, R. C., Greasley, P. J., Oscarsson, J., Boulton, D. W., & Hallow, K. M. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1987 · Cited by 7
Yanai, H., Yamaguchi, N., & Adachi, H. (2022) · Cardiology Research · doi:10.14740/cr1424 · Cited by 7
Khoo, K., Lew, J., Neef, P. A., Kearney, L., Churilov, L. P., Robbins, R., Tan, A., Hachem, M., Owen-Jones, L., Lam, Q. T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31473-8 · Cited by 7
Griffin, T. P., Islam, M. N., Blake, L., Bell, M., Griffin, M. D., & O’Shea, P. M. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0794-7026 · Cited by 7
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Investigation of expression and influence of CTGF and HO-1 in rats with diabetic retinopathy
Huang, Y., Qian, C., Zhou, J., & Xue, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8395 · Cited by 7
Managing diabetes patients in India: Is the future more bitter or less sweet?
Rajadhyaksha, V. (2018) · Perspectives in Clinical Research · doi:10.4103/picr.picr_161_17 · Cited by 7
Gazzaruso, C., Coppola, A., Montalcini, T., & Falcone, C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.30 · Cited by 7
Sanon, V., Patel, S., Sanon, S., Rodriguez, R., Pham, S., & Chilton, R. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s97619 · Cited by 6
“The EMPA-REG trial The EMPA-REG trial was a randomized controlled, doubleblinded trial on the cardiovascular safety of the SGLT2 inhibitor empagliflozin in a cohort of patients with type 2 diabetes at high cardiovascular risk.(18) The trial also highlighted the potential of empagliflozin to confer benefits on micro- a…”
BackgroundWang, X., Zhang, X., Zhang, W., Li, J., Weng, W., & Li, Q. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2409258 · Cited by 6
Ridwan, M. Q., Dimiati, H., Syukri, M., Lesmana, R., & Zaini, L. M. (2024) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v16i1.2776 · Cited by 6
Dayyih, W. A., Zakaraya, Z. Z., Hailat, M. M., Al-Tawarah, N. M., Alkharabsheh, S., Nadher, H. K., Hailat, Z., Alarman, S. M., Khaleel, A., & Awad, R. S. (2024) · Molecules · doi:10.3390/molecules29061236 · Cited by 6
Protective Mechanisms of SGLTi in Ischemic Heart Disease
Liao, L., Wang, T., Zhang, L., Yan, W., & Fan, X. (2024) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10513-x · Cited by 6
Szívelégtelenségben szenvedő betegek halálozása hazánkban 2017-ben
Tomcsányi, J. (2020) · Orvosi Hetilap · doi:10.1556/650.2020.31748 · Cited by 6
Managing the Burden of Dementia-Related Delusions and Hallucinations
Small (2020) · The Journal of Family Practice · doi:10.12788/jfp.0065 · Cited by 6
Kobrynska, O., & Didushko, О. М. (2022) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.18.8.2022.1220 · Cited by 6
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Sanz‐Cánovas, J., Ricci, M., Cobos-Palacios, L., Sampalo, A. L., Hernández-Negrín, H., Vázquez-Márquez, M., Mancebo-Sevilla, J. J., Álvarez-Recio, E., Lopez-Carmona, M. D., Velasco, M. Á. P., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2402036 · Cited by 6
Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease
Capelli, I., Ribichini, D., Provenzano, M., Vetrano, D., Aiello, V., Cianciolo, G., Vicennati, V., Tomassetti, A., Moschione, G., Berti, S., et al. (2023) · Life · doi:10.3390/life13041061 · Cited by 6
Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Jones, W. S., Butler, J., Shah, R. C., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.04.011 · Cited by 6
Yanagawa, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3014w · Cited by 6
SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure
Kobalava, Z. D., Lazarev, P. V., & Вадимовна, В. С. (2018) · Kardiologiia · doi:10.18087/cardio.2018.2.10087 · Cited by 6
Diabetes, and its treatment, as an effector of autonomic nervous system circuits and its functions
Espinoza, L., & Boychuk, C. R. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.06.006 · Cited by 6
Garnica-Cuéllar, J. C., Lavalle-González, F. J., Magaña-Serrano, J. A., Almeda-Valdés, P., Canto, J. A. C., Chávez-Iñiguez, J. S., Garza-García, C. A., González-Chávez, A., González-Gálvez, G., Medina-Chávez, J. H., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000596 · Cited by 11
A Rose by Any Other Name: Ketoacidosis Due to SGLT2 Inhibitors Reveals Latent Autoimmune Diabetes
Nodzynski, T., & Lee, T. C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.09.014 · Cited by 6
Sorokina, A. G., & Orlova, Y. A. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-11-142-147 · Cited by 6
Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?
Ferdinand, K. C., & Mahata, I. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.24 · Cited by 6
Researching trends on stroke: bibliometric analysis of the highly cited papers
Li, F., Shi, F., & Wang, S. (2024) · Frontiers in Stroke · doi:10.3389/fstro.2024.1447369 · Cited by 5
Li, F., Baheti, R., Jin, M., Xiong, W., Duan, J., Peng, F., & Wan, J. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01553-z · Cited by 5
Li, C., Ng, J. K., Chan, G. C., Fung, W. W., Chow, K. M., & Szeto, C. (2025) · Kidney Diseases · doi:10.1159/000545225 · Cited by 5
Effects of oral antidiabetic agents on the renin–angiotensin–aldosterone system
Yang, X., Qi, Y., Hao, J., Wei, H., Li, Z., Xu, M., Zhang, Y., & Liu, Y. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03830-w · Cited by 5
Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population
Kosyakovsky, L. B., de Boer, R. A., & Ho, J. E. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00686-6 · Cited by 6
Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis
Singh, A. K., & Singh, R. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196026 · Cited by 5
Nasser, S. A., Arora, N., & Ferdinand, K. C. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2312411 · Cited by 5
Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023)
Clodi, M., Saely, C. H., Hoppichler, F., Resl, M., Steinwender, C., Stingl, H., Wascher, T. C., Winhofer, Y., & Sourij, H. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02183-7 · Cited by 5
Relationship Between SGLT2 Inhibitors and Hemoglobin Levels: A Retrospective Observational Study
YOSHIDA, Y., TAKAHASHI, K., Hashimoto, R., Oya, T., & Sato, J. (2023) · In Vivo · doi:10.21873/invivo.13336 · Cited by 5
Yazdi, Z. S., Streeten, E. A., Whitlatch, H. B., Montasser, M. E., Beitelshees, A. L., & Taylor, S. I. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad554 · Cited by 5
Shared decision-making approach to type 2 diabetes management
MacDonald, B. J., McCormack, J. P., & Turgeon, R. D. (2024) · Canadian Family Physician · doi:10.46747/cfp.7005310 · Cited by 5
How many oral antidiabetic drugs before insulin?
Kelwade, J., Parekh, H., Dukle, V., & Sethi, B. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.195994 · Cited by 5
Kakuda, H., Kobayashi, J., Sakurai, M., Kakuda, M., & Takekoshi, N. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2806w · Cited by 5
Kaur, K. K., Allahbadia, G. N., & Singh, M. (2019) · Archives of Diabetes and Endocrine System · doi:10.22259/2638-4981.0201002 · Cited by 5
McRae, M., & Wang, C. C. L. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.012 · Cited by 7
SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics?
GEAVLETE, B. F., Popescu, R.-I., Iordache, V., Georgescu, D. E., & Geavlete, P. A. (2023) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2023.18.1.102 · Cited by 7
Algoritmo de tratamiento de la diabetes mellitus tipo 2. RedGDPS 2023
Soidán, F. J. G. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.2.art2 · Cited by 5
Woźniak, E., Świstek, M., Broncel, M., Bukowska, B., & Gorzelak‐Pabiś, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116065 · Cited by 5
Xie, T., & Zhao, L.-J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116343 · Cited by 5
Zhang, B., Gang, S., Li, Z., Gao, W., Tan, W., Liu, J., Zhang, B., Wu, J., Chen, R., Li, X. J., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001576 · Cited by 5
Ye, Z., Li, H., Lü, H., Su, Q., & Li, L. (2017) · Oncotarget · doi:10.18632/oncotarget.22959 · Cited by 5
Higashikawa, T., Ito, T., Mizuno, T., Ishigami, K., Kohori, M., Mae, K., Usuda, D., Takeshima, K., Takagi, S., Izumida, T., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4278 · Cited by 5
The year in cardiology 2019: heart failure
Cleland, J. G. F., Lyon, A. R., McDonagh, T. A., & McMurray, J. J. V. (2020) · Romanian Journal of Cardiology · doi:10.47803/rjc.2020.30.2.185 · Cited by 5
Rudofsky, G., Haenni, T., Xu, J., & JOHNSSON, E. K. (2017) · Experimental and Clinical Endocrinology & Diabetes Reports · doi:10.1055/s-0043-101823 · Cited by 5
Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Yanai, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.22 · Cited by 5
Shi, S., Li, X., Chen, Y., Li, J., & Dai, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70044 · Cited by 4
Lei, Y., Yao, S., Wang, Z., Tu, Q., Yuan, Z., & Jiang, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1506652 · Cited by 4
Cardiovascular complications in Diabetes: The role of NLRP3 inflammasome and targeted interventions
Jeyaraj, G. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100629 · Cited by 4
Bauer, K. I., Baker, D., Lerner, R., Koeck, T., Buch, G., Fischer, Z., Martens, R., Esenkova, E. E., Nuber, M., Andrade-Navarro, M. A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02916-0 · Cited by 6
Chanawong, A., Uitrakul, S., Incomenoy, S., & Poonchuay, N. (2023) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2023/5581417 · Cited by 5
Fókuszban a csökkent ejekciós frakciójú szívelégtelenség gyógyszeres kezelése
Muk, B. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.4.351 · Cited by 4
Chen, L., Zhou, N., & Zhang, L. (2024) · The Heart Surgery Forum · doi:10.59958/hsf.7627 · Cited by 4
Gan, L., Chen, P., Zhang, Z., He, X., Wu, X., Chen, Z., Wei, Q., & Wu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-94360-z · Cited by 4
Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes
Asrih, M., & Gariani, K. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666191105151828 · Cited by 4
SGLT2-Hemmer als Ursache für die Entstehung einer Ketoazidose
Emmelheinz, M., Roden, M., & Müssig, K. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-1011-8694 · Cited by 4
Managing Common Co-morbidities in Heart Failure
Sin, P. S., Sanjanwala, R., & Zieroth, S. R. (2020) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v15isp1.422 · Cited by 4
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 6
Farooq, M., & Jorde, U. P. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000424 · Cited by 5
Medication management for heart failure with reduced ejection fraction
Barry, A. R., Kosar, L., Koshman, S. L., & Turgeon, R. D. (2021) · Canadian Family Physician · doi:10.46747/cfp.6712915 · Cited by 4
Kieffer, C. M., & Robertson, A. S. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00098-y · Cited by 5
Aamir, A. H., Raja, U. Y., Qureshi, F. M., Asghar, A., Mahar, S. A., Ahmed, I., Ghaffar, T., Zafar, J., Hasan, M. I., Riaz, A., et al. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01213-1 · Cited by 4
Shami, D. A., SOUSOU, J. M., Batarseh, E., & Al-Azrai, L. (2023) · Cureus · doi:10.7759/cureus.33484 · Cited by 5
Demidova, T. Y., Izmaylova, M. Y., & Belova, K. M. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-172 · Cited by 4
Zhou, Y., Wang, F., Wen, F.-F., Li, C., & Ye, T.-T. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2250949 · Cited by 4
Wang, M., Li, M., Wang, L., Wang, F., Cao, X., Li, S., & Zheng, Z. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.04.009 · Cited by 4
Implications of CVD-REAL 2 study for Indian diabetic population
Chawla, R., & Jaggi, S. (2019) · Journal of Diabetology · doi:10.4103/jod.jod_48_18 · Cited by 4
Should CMR be the default imaging modality in clinical trials for heart failure?
Hundertmark, M. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-244 · Cited by 4
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 7
Job Satisfaction among Primary Health Care Workers in Buraidah, Qassim, Saudi Arabia
Aljumail, E., & Rabbani, U. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94173 · Cited by 4
The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
Koguchi, A., Adachi, H., & Yanai, H. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3220w · Cited by 4
Vargas, J. M., Rico-Fontalvo, J. E., Enrique Melgarejo, R., Castillo, G. A., Rincón, A. R., Gómez, A. M., Rojas, S. M., & Ibatá, L. (2020) · Revista Colombiana de Nefrología · doi:10.22265/acnef.7.1.372 · Cited by 9
Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure
Yanai, H. (2017) · Journal of Endocrinology and Metabolism · doi:10.14740/jem426w · Cited by 4
Dai, M., Jia, Z., Wang, H., Zheng, P., Xue, Y., Gong, K., & Zhao, R. (2025) · Inflammation · doi:10.1007/s10753-025-02309-1 · Cited by 4
Wang, W., Huang, Y., Wang, X., Gan, W., Zhao, S., Jin, L., & Tao, Y. (2026) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2026.03.003 · Cited by 5
Zhong, M., Wu, X., Liu, Y., Mao, Y., Liu, M., Liu, X., & Liu, Q. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07882-7 · Cited by 4
SYSTEMATIC REVIEW ON MEDICAMENTS USED IN MANAGEMENT OF DIABETES MELLITUS
Jamwal, A. (2020) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2020v12i8.38345 · Cited by 4
Optimizing Bone Health in Diabetes: Strategies for Fracture Risk Reduction in Public Healthcare
Nagendra, L., Agarwal, K., Patra, S., Bhattacharya, S., Gupta, L., Talwar, N., Rao, A., Gupta, A., Kamrul-Hasan, A. B. M., Dutta, D., et al. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01599-x · Cited by 3
Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
Garodia, N., Gupta, V., Canovatchel, W. J., Lokesh, B., & Santani, R. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_85_17 · Cited by 3
Kumar, S., Talwalkar, P., Das, S., & Goswami, S. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_161_17 · Cited by 3
Kato, E. T., & Goto, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17049 · Cited by 3
Promoting analysis of real-world data: Prospects for preventive cardiology in Japan
Yotsumoto, H., Kaneko, H., Itoh, H., Kamon, T., Kiriyama, H., Fujiu, K., Takeda, N., Morita, H., & Komuro, I. (2021) · Global Health & Medicine · doi:10.35772/ghm.2020.01077 · Cited by 3
Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease
Swanner, A. A., Hawley, C. E., Li, K., Triantafylidis, L. K., Li, J., & Paik, J. M. (2021) · Clinical Diabetes · doi:10.2337/cd21-0078 · Cited by 3
Alasmari, I. H., Saleh, M. M. A., Alahmari, M. A., Asiri, S. M., & Asiri, A. Y. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94184 · Cited by 3
Alomary, S. A., Alorainy, B. A., Albargan, N. S., Alotaibi, F. Z., & Alkholaiwi, F. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94191 · Cited by 3
KOVIL, R. R., Chawla, M. S., Shah, T. V., Sahoo, A., Makkar, B. M., Kesavadev, J., Seshadri, K., TIWASKAR, M. H., Rajput, R., Phatak, S., et al. (2022) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0076 · Cited by 3
Jain, R., Stone, J. A., Agarwal, G., Andrade, J. G., Bacon, S., BAJAJ, H. S., Baker, B., Cheng, G., Dannenbaum, D. A., Gelfer, M., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.220138-f · Cited by 4
A Systematic Overview of Bexagliflozin
Dalal, D., Kant, R., Attri, K., Kapoor, G., Nagarajan, K., Bhutani, R., Sharma, K., Kaushik, U., Yadav, M., & Jamwal, N. S. (2023) · Asian Journal of Pharmaceutical Research and Health Care · doi:10.4103/ajprhc.ajprhc_25_23 · Cited by 3
Romero, A., Saldarriaga, C., Ramos, C. E., Quesada, D., Chazzin, G., Fernández, F. N. G., Pow-Chon-Long, F., Alarco, W., Hurtado, P. E., Magaña, J. A., et al. (2023) · Archivos de cardiología de México · doi:10.24875/acm.23000059 · Cited by 3
Rahhal, A. A. A., Hamamyh, T., Chapra, A. F., Zaza, K. J., Najim, M., Hemadneh, M. K. E., Faraj, H. A. A., Kanjo, W., Yasin, A. K. A., Toba, H., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1383669 · Cited by 3
Pathophysiology, life style intervention and complications of Type-2 diabetes: A review
Basak, M., & Laskar, M. A. (2024) · Journal of Applied Pharmaceutical Research · doi:10.69857/joapr.v12i3.482 · Cited by 8
Morales, J., & Assumpcao‐Morales, M. (2019) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2019.12.00450 · Cited by 3
Metadata
- Authors
- Sarafidis, P. A., & Τσάπας, Α.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-17
- Volume
- 374
- Issue
- 11
- Pages
- 1092-1094
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2297835124
- Cited by
- 700
- References
- 9
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 77 · 2023: 91 · 2022: 71 · 2021: 95 · 2020: 93 · 2019: 61 · 2018: 57 · 2017: 62 · 2016: 34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, type 2 diabetes, cardiovascular outcomes, mortality, SGLT2 inhibitors, cardiovascular risk reduction
- MeSH terms
- Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
